	US 11,666,627 B2
	Proteins for the treatment of epithelial barrier function disorders
Andrew Wonhee Han, San Francisco, CA (US); Andrew Whitman Goodyear, Pacifica, CA (US); Tarunmeet Gujral, Foster City, CA (US); Todd Zachary Desantis, Livermore, CA (US); Karim Dabbagh, Mountain View, CA (US); Toshihiko Takeuchi, Oakland, CA (US); Ye Jin, Danville, CA (US); Michi Izumi Willcoxon, Palo Alto, CA (US); and Stefanie Banas, Concord, CA (US)
Assigned to Second Genome, Inc., Brisbane, CA (US)
Filed by Second Genome, Inc., South San Francisco, CA (US)
Filed on Jan. 28, 2019, as Appl. No. 16/259,286.
Application 16/259,286 is a division of application No. 15/947,263, filed on Apr. 6, 2018, granted, now 10,251,933.
Claims priority of provisional application 62/611,334, filed on Dec. 28, 2017.
Claims priority of provisional application 62/607,706, filed on Dec. 19, 2017.
Claims priority of provisional application 62/482,693, filed on Apr. 7, 2017.
Prior Publication US 2020/0171125 A1, Jun. 4, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/16 (2006.01); C07K 2/00 (2006.01); A61P 37/02 (2006.01); A61P 1/04 (2006.01); C07K 14/195 (2006.01); A61K 38/00 (2006.01); C07K 14/33 (2006.01)

CPC A61K 38/16 (2013.01) [A61P 1/04 (2018.01); A61P 37/02 (2018.01); C07K 2/00 (2013.01); C07K 14/195 (2013.01); A61K 38/00 (2013.01); C07K 14/33 (2013.01)]

16 Claims

1. A method of increasing epithelial barrier integrity in the gut of a patient, the method comprising:

administering to a patient in need thereof a pharmaceutical composition, comprising:

i) a therapeutic protein comprising the amino acid sequence of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, or SEQ ID NO: 19; and

ii) a pharmaceutically acceptable carrier,

wherein the patient has a disorder selected from the group consisting of: inflammatory bowel disease, pouchitis, irritable bowel syndrome, celiac disease, necrotizing enterocolitis, short bowel syndrome, GI mucositis, chemotherapy-induced mucositis, radiation-induced mucositis, oral mucositis, and pediatric versions of the aforementioned diseases.